Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Overview of attention for article published in Biomarker Research, November 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

So far, Altmetric has seen 14 X posts from 12 X users, with an upper bound of 48,480 followers.

RT @Tucker_MatthewD: Our paper on the baseline neutrophil-to-eosinophil ratio and response to nivo/ipi in patients with mRCC is out now! @V…

RT @TiansterZhang: 👏👏👏 congrats to Matt and the team — cohorts of patients from @VUMC_Cancer & @DukeCancer showing predictive utility of ba…

RT @Tucker_MatthewD: Our paper on the baseline neutrophil-to-eosinophil ratio and response to nivo/ipi in patients with mRCC is out now! @V…

RT @Tucker_MatthewD: Our paper on the baseline neutrophil-to-eosinophil ratio and response to nivo/ipi in patients with mRCC is out now! @V…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.